CALR: the new biomarker for myeloproliferative neoplasm (MPN) research

CALR: the new biomarker for myeloproliferative neoplasm (MPN) research

March 21, 2017

Polycythemia vera, essential thrombocythemia and primary myelofibrosis, the three major forms of MPN, are most often associated with Janus kinase 2 (JAK2) mutations. However, a large subset of MPN are JAK2 V617F-negative.

Two large scale studies on MPN showed that many of the JAK2 V617F-negative MPNs were positive for both somatic Type I and Type 2 mutations in calreticulin (CALR).

How can you reliably detect somatic mutations in exon 9 of the CALR gene? Find out now!

 

 

 

Blood-based biomarkers for COVID-19

Blood-based biomarkers for COVID-19

Establishing biomarkers for COVID-19 that indicate which patients are likely to develop severe disease could help clinicians to categorize patients earlier, improve prognosis and prioritize treatment.

June 23, 2020 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us